Zai Qi Wang
Directeur Général chez InxMed Biotechnology Nanjing Co., Ltd.
Postes actifs de Zai Qi Wang
Sociétés | Poste | Début | Fin |
---|---|---|---|
InxMed Biotechnology Nanjing Co., Ltd.
InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | Directeur Général | 01/11/2018 | - |
Président | 01/11/2018 | - | |
Fondateur | 01/01/2018 | - |
Historique de carrière de Zai Qi Wang
Statistiques
Internationale
Chine | 2 |
Opérationnelle
Chief Executive Officer | 1 |
Chairman | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
InxMed Biotechnology Nanjing Co., Ltd.
InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | Health Technology |
- Bourse
- Insiders
- Zai Qi Wang
- Expérience